Doxycycline or moxifloxacin for the management of community-acquired pneumonia in the UK?
Int J Antimicrob Agents. 2008 Aug;32(2):101-5
Authors: Ludlam HA, Enoch DA
Macrolide monotherapy is currently recommended as first-line treatment of mild-to-moderate community-acquired pneumonia (CAP) in penicillin-intolerant/allergic individuals in the UK. However, resistance rates among the commonest cause, Streptococcus pneumoniae, now exceed 10% in the UK and a review of alternative agents is therefore timely. This review considers the relative merits of two agents, doxycycline and moxifloxacin, which are candidates to replace macrolides for second-line therapy of non-severe CAP.
PMID: 18571380 [PubMed - indexed for MEDLINE]